-
Signature
-
/s/ Pamela Sergeeff, Attorney-in-fact
-
Issuer symbol
-
FRSH
-
Transactions as of
-
01 Oct 2023
-
Net transactions value
-
-$164,359
-
Form type
-
4
-
Filing time
-
03 Oct 2023, 17:03:53 UTC
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
FRSH |
Class A Common Stock |
Award |
$0 |
+558 |
+3.7% |
$0.000000 |
15,482 |
01 Oct 2023 |
Direct |
F1 |
| transaction |
FRSH |
Class A Common Stock |
Conversion of derivative security |
$0 |
+8,433 |
+54% |
$0.000000 |
23,915 |
02 Oct 2023 |
Direct |
|
| transaction |
FRSH |
Class A Common Stock |
Sale |
$164,359 |
-8,433 |
-35% |
$19.49 |
15,482 |
02 Oct 2023 |
Direct |
F2, F3 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
FRSH |
Restricted Stock Units |
Options Exercise |
$0 |
-9,370 |
-4.2% |
$0.000000 |
215,630 |
01 Oct 2023 |
Class B Common Stock |
9,370 |
|
Direct |
F4, F5 |
| transaction |
FRSH |
Class B Common Stock |
Options Exercise |
$0 |
+9,370 |
+21% |
$0.000000 |
52,998 |
01 Oct 2023 |
Class A Common Stock |
9,370 |
|
Direct |
F6 |
| transaction |
FRSH |
Class B Common Stock |
Conversion of derivative security |
$0 |
-8,433 |
-16% |
$0.000000 |
44,565 |
02 Oct 2023 |
Class A Common Stock |
8,433 |
|
Direct |
F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: